Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry's top players, the U.S. government is back for round 2, this time lining up agreements with a host of medium-sized biopharmas under President Trump's 'most favored nation' agenda.
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry's top players, the U.S.
government is back for round 2, this time lining up agreements with a host of medium-sized biopharmas under President Trump's 'most favored nation' agenda.
The page is ready to read now. The fuller skim-friendly version will appear here automatically.
Some four months after the White House inked the last of its expected drug pricing deals with 17 of the industry's top players, the U.S. government is back for round 2, this time lining up agreements with a host of medium-sized biopharmas under President Trump's 'most favored nation' agenda.
Open the app view to save this story, compare related coverage, and continue from the same source.